Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS).

Giulia Chiabotto,Maria Laura Centomo,Alessandra Merlini,Lorenzo D'Ambrosio,Dario Sangiolo,Umberto Miglio,Maja Todorovic,Lucia Napione,Enrico Berrino,Federica Capozzi,Tiziana Venesio,Elena Maldi,Anna Sapino,Massimo Aglietta,Giovanni Grignani,Ymera Pignochino

Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS).

2019

Giulia Chiabotto
Maria Laura Centomo
Alessandra Merlini
Lorenzo D'Ambrosio
Dario Sangiolo
Umberto Miglio
Maja Todorovic
Lucia Napione
Enrico Berrino
Federica Capozzi
Tiziana Venesio
Elena Maldi
Anna Sapino
Massimo Aglietta
Giovanni Grignani
Ymera Pignochino

e22509Background: Receptor tyrosine kinases (RTKs) and their signal transducers are suitable targets for the treatment of advanced OS. We evaluated the antitumor activity of the RTK inhibitor P and...

Keywords:

Pazopanib
Receptor tyrosine kinase
Osteosarcoma
Cancer research
Pathology
Trametinib
Medicine
antitumor activity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations